Establishment of Real Time Allele Specific Locked Nucleic Acid Quantitative PCR for Detection of HBV YIDD (ATT) Mutation and Evaluation of Its Application

Yongbin Zeng1,2,* , Dezhong Li3,9 , Wei Wang1,2 , Mingkuan Su1,2 , Jinpiao Lin1,2 , Huijuan Chen1,2 , Ling Jiang1,2 , Jing Chen1,4 , Bin Yang1,2 , Qishui Ou1,2*

1 First Clinical College, Fujian Medical University, Fuzhou, China, 2 Department of Laboratory Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China, 3 Department of Laboratory Medicine, The Armed Police Hospital of Fujian, Fuzhou, China, 4 Center of Liver Diseases, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China

Abstract

Background: Long-term use of nucleos(t)ide analogues can increase risk of HBV drug-resistance mutations. The rtM204I (ATT coding for isoleucine) is one of the most important resistance mutation sites. Establishing a simple, rapid, reliable and highly sensitive assay to detect the resistant mutants as early as possible is of great clinical significance.

Methods: Recombinant plasmids for HBV YMDD (tyrosine-methionine-aspartate-aspartate) and YIDD (tyrosine-isoleucine-aspartate-aspartate) were constructed by TA cloning. Real time allele specific locked nucleic acid quantitative PCR (RT-AS-LNA-qPCR) with SYBR Green I was established by LNA-modified primers and evaluated with standard recombinant plasmids, clinical templates (the clinical wild type and mutant HBV DNA mixture) and 102 serum samples from nucleos(t)ide analogues-experienced patients. The serum samples from a chronic hepatitis B (CHB) patient firstly received LMV mono therapy and then switched to LMV + ADV combined therapy were also dynamically analyzed for 10 times.

Results: The linear range of the assay was between $1 \times 10^6$ copies/µl and $1 \times 10^5$ copies/µl. The low detection limit was $1 \times 10^2$ copies/µl and $1 \times 10^3$ copies/µl in the wild-type background of $1 \times 10^9$ copies/µl, $1 \times 10^5$ copies/µl and $1 \times 10^3$ copies/µl, respectively. The sensitivity of the assay in detection of clinical samples was 0.03%. The complete coincidence rate between RT-AS-LNA-qPCR and direct sequencing was 91.2% (93/102), partial coincidence rate was 8.8% (9/102), and no complete discordance was observed. The two assays showed a high concordance ($Kappa = 0.676, P = 0.000$). Minor variants can be detected 18 weeks earlier than the rebound of HBV DNA load and alanine aminotransferase level.

Conclusions: A rapid, cost-effective, high sensitive, specific and reliable method of RT-AS-LNA-qPCR with SYBR Green I for early and absolute quantification of HBV YIDD (ATT coding for isoleucine) variants was established, which can provide valuable information for clinical antiretroviral regimens.

Citation: Zeng Y, Li D, Wang W, Su M, Lin J, et al. (2014) Establishment of Real Time Allele Specific Locked Nucleic Acid Quantitative PCR for Detection of HBV YIDD (ATT) Mutation and Evaluation of Its Application. PLoS ONE 9(2): e90029. doi:10.1371/journal.pone.0090029

Editor: Bruno Verhasselt, Ghent University, Belgium

Received July 2, 2013; Accepted January 28, 2014; Published February 28, 2014

Copyright: © 2014 Zeng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The study was supported by the grants from Key Project of Industry-university Cooperation of Fujian province (2013Y4002), Social Key Project of Fujian Technology Department (2011Y0032; http://www.fjkt.gov.cn/) and National Natural Science Foundation of China (81371888). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: ouqishui@163.com

† These authors contributed equally to this work.

Introduction

Nucleos(t)ide analogues (NAs), such as Lamivudine (LMV), Telbivudine (LdT), Adefovir Dipivoxil (ADV) and Entecavir (ETV), are widely used for the treatment of chronic hepatitis B [1]. Unfortunately, long-term use of these drugs can increase risk of HBV drug-resistance mutations. The main site associated with resistance is mainly in the highly conserved tyrosine-methionine-aspartate-aspartate (YMDD) motif of the C domain of HBV polymerase. Methionine substituted by valine or isoleucine in codon 204 (i.e., rtM204V/I) were confirmed to confer resistance to LMV. The rtM204I can not only cause the selection of Lamivudine and Telbivudine resistance, but can also lead to Entecavir-resistance [2]. For many years, early detection of HBV drug-resistance mutants has received much attention due to its importance for the strategic treatment of chronic hepatitis B virus-infected patients.

Lots of highly sensitive detection technologies, such as next-generation sequencing, peptide nucleic acid-mediated PCR clamping, line probe assay (LiPA), liquid array, mass spectrometric analysis, have become available in recent years [3–7]. However, some limitations have also been found, i.e., special instruments may be present, testing costs may be high in some technologies,
etc. Consequently, their wide application are somewhat restricted in clinical laboratories.

Although real time PCR such as allele-specific PCR (AS-PCR) for the detection of HBV mutants was reported years ago, little attention has been paid to AS-PCR using LNA-modified primers. Locked nucleic acid (LNA) is a nucleic acid analog with a 2-O, 4-C methylene bridge which generally increases its melting temperature. PCR primers modified with LNA nucleotides show very accurate mismatch discrimination and high specificity [8]. In the present study, we establish a novel assay named real time allele specific locked nucleic acid quantitative PCR (RT-AS-LNA-qPCR) with SYBR Green I for detection of HBV YIDD (ATT coding for isoleucine) mutation, and focus on its methodological evaluation and clinical application.

Materials and Methods

Patients

112 serum samples were obtained from chronic hepatitis B patients receiving nucleos(t)ide analogues (NAs) therapy in The First Affiliated Hospital of Fujian Medical University. 83 were male and 29 were female. The mean age was 38±13 years. Clinical data such as alanine aminotransferase (ALT) was measured. The study was in accordance with the approval of the ethics committee of The First Affiliated Hospital of Fujian Medical University and the ethical principles of the 1975 Declaration of Helsinki. Written informed consent was also obtained from each patient.

Serum HBV DNA extraction

HBV DNA was extracted from serum samples using viral genomic DNA extraction kit (Beijing Xinning Company, China) according to the manufacturer’s instruction and stored at −20°C until used.

Primers for RT-AS-LNA-qPCR

Primers for RT-AS-LNA-qPCR were designed using Primer Premier 5.0 software (Premier Biosoft International, USA) according to the principle of AS-PCR technique. The design guidelines were provided by Exiqon (http://www.exiqon.com/oligo-tools). The polymorphism analysis of the most common genotypes (B and C) in China obtained from GenBank was performed on DNAMAN software (Lynnon BioSoft, Canada). The forward primer (KF) was at nucleotide positions 396~416 for the amplification of both YMDD and YIDD (tyrosine-isoleucine-aspartate-aspartate). The reverse primers modified with a LNA at the 3'-end terminal position (L1) or penultimate position (L2) were designed to detect YIDD and YMDD, respectively. Wild type primer with last position of the nucleic acids lock (L2) was synthesized. Non-degenerated primers including the forward (KF) and the reverse (L1 and L2) with exact match to mutant and wild type plasmids were also included in this study (Table 1).

Preparation of YMDD and YIDD plasmids for calibration curves

Two clinical samples harboring wild-type (YMDD, ATG coding for methionine) and mutant (YIDD, ATT coding for isoleucine) DNA sequences confirmed by direct sequencing were used for plasmids construction. Target DNA was amplified with primers (KF, L1 and L2) listed in Table 1. PCR was performed in a 25-μl reaction mixture containing 12.5 μl of 2× HotStart Taq PCR Mastermix (Tiangen, China), 0.7 μl of each primer (10 μM), 9.1 μl of ddH2O and 2.0 μl of DNA template. Thermal cycling conditions were as follows: initial denaturation at 94°C for 3 min, then 35 cycles with denaturation at 94°C for 30 s, annealing at 60°C for 30 s and extension at 72°C for 45 s, and a final elongation step at 72°C for 10 min. PCR products were electrophoresed on a 2.0% agarose gel and purified via PCR purification kit (Sangon, China), then cloned into pMD 18-T vector (Takara, Japan) and transformed into E. coli DH5α competent cell (Takara, Japan). The positive plasmids were sequenced and then isolated using Tiangen mini plasmid isolation kit (Tiangen, China). Plasmids were quantified by NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, USA). The corresponding copy number were calculated and 10-fold serially diluted from 1×10^10 copies/μl to 1×10^0 copies/μl using Easy Dilution Buffer (Takara, Japan) to generate standard concentrations.

Preparation of different proportions of clinical mutant template

DNA from clinical sample harboring rtM204I confirmed by sequencing were mixed with wild-type clinical sample in different proportions. Specifically, clinical template containing 50% mutant HBV DNA was obtained by mixing 10 μl 1×10^10 copies/μl clinical mutant DNA sample with 10 μl 1×10^9 copies/μl clinical wild-type DNA sample; and clinical template containing 25% mutant HBV DNA was obtained by mixing 5 μl mutant DNA with 15 μl wild-type DNA. Clinical templates containing different proportions of mutant DNA (i.e., 20%, 10%, 5%, 1%, 0.5%, 0.05%, 0.04%, 0.03%, 0.02% and 0.01% of mutants) were also prepared in a similar way.

RT-AS-LNA-qPCR

RT-AS-LNA-qPCR assay was performed on ABI 7500 Real-Time PCR system (Life Technologies, USA). The 25-μl PCR amplification reaction mixtures contained 12.5 μl of 2× SYBR Premix Ex Taq™ (Takara, Japan), 0.7 μl of each primer (10 μM), 0.5 μl of 50× ROX II reference dye (Takara, Japan), 8.6 μl of ddH2O and 2.0 μl of DNA template. Real time PCR conditions were: initial denaturation at 95°C for 30 s, followed by 40 cycles of denaturation at 95°C for 5 s, and annealing/extension at 60°C for 30 s. The post-amplification melting curve analysis was performed to confirm whether the nonspecific amplification was generated from primer-dimers.

Direct Sequencing

To evaluate the performance of RT-AS-LNA-qPCR, all clinical samples were subjected to direct sequencing. The HBV DNA

### Table 1. Primers for RT-AS-LNA-qPCR.

| Primer names | Sequences (5'-3') | Positions (nt) | Length (bp) |
|--------------|------------------|---------------|-------------|
| KF | TCAATTCTCTKCATGC | 396~416 | 21 |
| L1 | CCCAAWACCACATCAC+CA | 741~759 | 19 |
| L2 | CCCAAWACCACATCAC+CA | 740~758 | 19 |
| L2n | CCCAAWACCACATCAC+CA | 741~759 | 19 |
| L2l | CCCAAWACCACATCAC+CA | 740~758 | 19 |
| KFn | TCACTCTCTGTGCATGC | 396~416 | 21 |

KF/KFn, indicate the common forward primers to all reactions. L1/L2/L1/L2, indicate specific RT-AS-LNA-qPCR reverse primers. M indicates A/C; K indicates A/G; T indicates A/C; W indicates A/T; G indicates A/C; + indicates LNA nucleotides. doi:10.1371/journal.pone.0090029.t001
fragments containing the polymerase RT (reverse-transcriptase) domain were amplified using HBV sequencing kit (Shenyou, Shanghai) according to the manufacturer’s instruction. Purified PCR products were sequenced with ABI 3130 genetic analyzer (Life Technologies, USA).

Statistical analysis
Results obtained from RT-AS-LNA-qPCR were compared with those from sequencing. The statistical analysis was performed using statistical analysis software SPSS version 16.0 (SPSS Inc, USA) and GraphPad Prism software version 5.0 (GraphPad Software, USA). Complete concordance was considered if the results detected by RT-AS-LNA-qPCR and direct sequencing were identical. Partial concordance was considered if (1) RT-AS-LNA-qPCR showed a mixture of wild-type and mutant sequences, whereas sequencing showed only one of the two results, or (2) sequencing showed a mixture of wild-type and mutant sequences but RT-AS-LNA-qPCR showed only a wild-type or a mutant sequence. Complete discordance was considered if one test showed a wild type and the other showed a mutant. Concordance was assessed by Cohen’s *Kappa* test. A *P*<0.05 was considered statistically significant.

Results
Identification of recombinant plasmids by sequencing
The pMD-18-YMDD and pMD-18-YIDD recombinant clones were picked out and sequenced. The obtained DNA sequences were subjected to BLAST alignment against HBV genome database (http://www.ncbi.nlm.nih.gov/BLAST/). Blast results indicated the sequences were completely consistent with HBV reference genome. Therefore, the pMD-18-YMDD and pMD-18-YIDD recombinant plasmids were successfully constructed.

Linear range and detection limit

| Concentration (copies/µl) | Ct Values |
|--------------------------|-----------|
| 1×10^5                   | 8.7 ± 1.2 |
| 1×10^6                   | 8.0 ± 1.1 |

The linear range and detection limit of RT-AS-LNA-qPCR was determined using 10-fold dilutions of wild-type DNA from 1×10^5 to 1×10^7 copies/µl (Figure 1 and Figure 2). There was an excellent linear correlation between the cycle number and the HBV DNA copy number from the concentration of 1×10^5 copies/µl to 1×10^7 copies/µl with correlation coefficients of 0.999 and 0.984 for the wild-type and mutant target sequences, respectively. The amplification efficiency was 94.9% and 96.3% for wild-type and mutant standard curves, respectively. Experiments using degenerated primers against each pure polymorphic templates (genotype B and C) were also done, and no differences were observed for the linear range and the detection limit (Figure S1).

Specificity test
The cross-reactivity test was carried out using a dilution series of the template i.e., different concentrations of pMD-18-YMDD recombinant plasmids (1×10^5 copies/µl~1×10^7 copies/µl) were amplified with mutant specific and wild-type specific primers, respectively, and so were the pMD-18-YIDD plasmids. As shown in Figure 3, no nonspecific amplification phenomenon was observed by mutant specific primers set (KF/L1), but, nonspecific amplification with the wild-type specific primers set (KF/L2) was detected at the concentration equal to or above 1×10^6 copies/µl. However, the observed copy number was less than the expected copy number at least 4 logs. Interestingly, there was no nonspecific amplification observed when the mismatch template was below 1×10^6 copies/µl. The priming efficiency of L2 and L2 was compared and no difference was observed (Figure S2: The Ct values were found to be almost the same for primer L2 and primer L2 when the same plasmid concentration was included in the test). The specificity of L2 was also compared with L2, while 1×10^5 copies/µl mutant DNA was added to the PCR reaction system, Ct (cycle threshold) values were 27.0 and 25.94 for L2 and L2, respectively; when the template was 1×10^6 copies/µl, the Ct values were 34.00 and 32.77 respectively. The Ct values were 36.97 and undetectable respectively, when mutant DNA was 1×10^7 copies/µl. These results indicated the specificity of L2 was higher than L2 (Figure S2).

Accuracy test
To assess the accuracy, a mixture of known quantity of wild-type and mutant standard plasmids was used to generate different proportions of mutant DNA, and both wild-type and mutant DNA were quantitatively analyzed by RT-AS-LNA-qPCR. As indicated in Figure 4, there was a significant linear correlation (*R^2* = 0.9907, *P*<0.0001) between actual proportion of mutant and calculated proportion of mutant for HBV standard plasmid at the concentration of 1×10^5 copies/µl.

Reproducibility test
High (1×10^7 copies/µl), medium (1×10^5 copies/µl) and low (1×10^4 copies/µl) concentrations of YMDD and YIDD recombinant plasmids were used as templates for 20 separate, simultaneous measurements by RT-AS-LNA-qPCR. The intra-run coefficient of variation (CV) was 0.74%, 0.91% and 1.07% for YMDD plasmids and 0.42%, 0.75% and 0.29% for YIDD plasmids. The quantitative assay was also done for 20 days consecutively. The inter-run CV was 1.12%, 1.79% and 2.10% for YMDD plasmids and 2.72%, 1.89% for YIDD plasmids.

Sensitivity test
A mixture of the dilution series of mutant plasmids with different fixed concentrations of wild-type DNA (1×10^5 copies/µl, 1×10^6 copies/µl and 1×10^7 copies/µl, respectively) were tested with mutant primer to determine the minimum mutant DNA concentration at which RT-AS-LNA-qPCR could accurately and steadily quantify. The 100% pure wild-type DNA and no-template control were also tested. Results (Figure 5 and Figure S3) showed the assay could accurately and steadily detect 1×10^5 copies/µl of mutant in the three different fixed concentrations of wild-type DNA, meaning that the sensitivity was 10^-5, 10^-6 and 10^-7 in the wild-type background of 1×10^5 copies/µl, 1×10^6 copies/µl and 1×10^7 copies/µl, respectively. Figure 5B showed it began to deviate from linearity when the concentration of mutant DNA was below 1×10^5 copies/µl. The sensitivity test was also carried out using non-degenerated primers (KF and L1) with exact match to mutant plasmids and there was no difference in detection sensitivity using the non-degenerated primers and the degenerated primers (Figure S4).

Clinical utility and reproducibility
The sensitivity was estimated using the different proportions of mutant above-mentioned (5%, 1%, 0.5%, 0.05%, 0.04%, 0.03%, 0.02% and 0.01%, respectively) by RT-AS-LNA-qPCR. We found that 0.03% of mutants could be accurately and steadily quantified by RT-AS-LNA-qPCR. Whereas the amplification curves of both 0.02% and 0.01% of mutants could not be discriminated from that of 0.03% of mutants (Figure 6). So 0.03% was regarded as the sensitivity of the assay of clinical samples with the most common polymorphisms.
Figure 1. Amplification plot and standard curve of RT-AS-LNA-qPCR for pMD-18-YMDD. (A) Amplification plot with different colors represented different concentrations of pMD-18-YMDD plasmids which were illustrated in the figure. (B) Standard curve of pMD-18-YMDD: Y = -3.478X+41.654 (R^2 = 0.999).

doi:10.1371/journal.pone.0090029.g001

Figure 2. Amplification plot and standard curve of RT-AS-LNA-qPCR for pMD-18-YIDD. (A) Amplification plot with different colors represented different concentrations of pMD-18-YIDD plasmids which were illustrated in the figure. (B) Standard curve of pMD-18-YIDD: Y = -3.413X+37.793 (R^2 = 0.984).

doi:10.1371/journal.pone.0090029.g002
To demonstrate reproducibility of quantification, the intra-run and inter-run reproducibility tests using clinical samples were also done. Repeated analysis demonstrated good reproducibility when the proportions of mutants was 0.03%.

Sensitivity comparison of RT-AS-LNA-qPCR with sequencing analysis on clinical samples
Clinical samples containing different proportions (50%, 25%, 20%, 10%, 5%, 1%, 0.5%, 0.05%, 0.01%) of rtM204I were used to compare the sensitivity of RT-AS-LNA-qPCR with sequencing. As indicated in Table 2, RT-AS-LNA-qPCR could detect rtM204I at a proportion as low as 0.01% (detection limit) of the total population, whereas sequencing analysis only detect at a proportion of 10%.

Comparison of RT-AS-LNA-qPCR with direct sequencing
102 NAs-experienced patients' sera were parallel analyzed by RT-AS-LNA-qPCR and direct sequencing. As shown in Table 3, among the 102 samples analyzed, 85 YMDD, 4 YIDD and 13 mixtures of YMDD + YIDD were detected by RT-AS-LNA-qPCR. By comparing the results obtained from RT-AS-LNA-qPCR with those from sequencing, the complete coincidence rate was 91.2% (93/102), partial coincidence rate was 8.8% (9/102), and no complete discordance was observed. Thus the two assays showed a high concordance (kappa = 0.676, P = 0.000). Among the 6 partial concordant results (Only YIDD was detected by direct sequencing), the proportion of variants ranged from 80.8% to 99.8% of the total viral population was calculated by RT-AS-LNA-qPCR (Table 4). Among another 3 samples collected from CHB patients who were highly suspicious of drug resistance, only wild-type DNA was detected at rt204 by direct sequencing, however, both wild-type and mutant were detected by RT-AS-LNA-qPCR, and the proportion of mutant was only 8.4%, 9.8% and 9.5%, respectively, which was below the sensitivity of direct sequencing. 3 typical samples whose detected results were partially concordant between direct sequencing and RT-AS-LNA-qPCR were selected for cloning sequencing; and the established method is consistent with the cloning sequencing finding. The typical cloning sequencing chromatograms of HBV rt204 were showed in Figure 7.

Dynamic analysis of wild-type and mutant HBV DNA in a CHB patient by RT-AS-LNA-qPCR
A 48-week-follow-up study of dynamic of YMDD and YIDD HBV serum DNA levels and ALT levels during first LMV mono therapy and then LMV + ADV combined therapy was illustrated in Figure 8. As can be seen, HBV DNA level and ALT level declined substantially at the first 7 weeks and no YIDD variants were detectable at that time. However, at week 17, a minor fraction of YIDD variants had already been detected, accounting for 13.7%, 18 weeks before the rebound of HBV DNA load and alanine aminotransferase level. It was indicated that variants had become the predominant population with a percentage of 58.3% 11 weeks later. At week 36, YIDD variants population increased to 100%. ADV was added to ongoing lamivudine treatment at that time point. The bi-therapy decreased HBV DNA, however, very slowly; and variants remained the predominant population.

Discussion
HBV drug resistant mutants are confirmed to exist in CHB patients prior to the initiating antiviral therapy with NAs. Previous researches have documented that the minor preexistence mutants...
can be gradually selected to become the dominant species under dual pressures of NAs and host immunity, and finally precede the occurrence of viral breakthrough or biochemical breakthrough [9]. Therefore, establishing a simple, rapid, reliable and highly sensitive assay to detect the resistant mutants as early as possible and analysis of their evolution during NAs-experienced are of great clinical significance.

A number of techniques regarding HBV mutants detection have been described. Direct sequencing, a qualitative assay, is considered to be the golden standard for HBV drug-resistance mutations detection, which is applied widely in clinical laborato-

**Table 2. Detection sensitivity comparison of RT-AS-LNA-qPCR and sequencing on clinical samples containing different proportions of rtM204I variant.**

| Proportions of rtM204I | RT-AS-LNA-qPCR | Sequencing |
|------------------------|----------------|------------|
| 50%                    | M/I            | M/I        |
| 25%                    | M/I            | M/I        |
| 20%                    | M/I            | M/I        |
| 10%                    | M/I            | M/I        |
| 5%                     | M/I            | M         |
| 1%                     | M/I            | -          |
| 0.5%                   | M/I            | -          |
| 0.05%                  | M/I            | -          |
| 0.04%                  | M/I            | -          |
| 0.03%                  | M/I            | -          |
| 0.02%                  | M/I            | -          |
| 0.01%                  | M/I            | -          |
| NTC                    | N              | N          |

M: Methionine; I: Isoleucine; -: not performed; NTC: no-template control; N: undetectable.

doi:10.1371/journal.pone.0090029.t002
LNA-modified primers and SYBR Green I. A few AS-PCR assays have been established taking advantage of HBV variants by AS-PCR [11–13], however, to our knowledge, there have been several studies with respect to the detection of a factor that would determine whether AS-PCR works specifically. Basically speaking, primer design is the most important reduction or to avoid false positive results by the optimization of mutation detection. However, it would be very important to reduce or to avoid false positive results by the optimization of mutation detection. Therefore, so far it has been used only for research purposes and not suitable for clinical use.

Allele-specific PCR, has also been termed amplification refractory mutation system PCR, selective PCR or mismatch PCR, which is a convenient and easily performed assay for mutation detection. However, it would be very important to reduce or to avoid false positive results by the optimization conditions. Basically speaking, primer design is the most important factor that would determine whether AS-PCR works specifically. There have been several studies with respect to the detection of HBV variants by AS-PCR [11–13], however, to our knowledge, few AS-PCR assays have been established taking advantage of LNA-modified primers and SYBR Green I.

Locked nucleic acid is a special nucleic acid analog with a 2-oxygen and 4-carbon atoms methylene bridge that locks the ribose group into the C3-endo conformation, thus, decreases ribosome structure flexibility and increases the phosphate backbone stability. It is generally accepted that LNA increases the melting DNA heteroduplex temperature between 1–8 °C per LNA nucleotide [8,14].

To date, many reports have documented that primers at or near 3'-end modified with LNA nucleotides can be applied to improve the mismatch discrimination ability of allele-specific PCR assay [8,14,15]. But data about this application in HBV drug-resistance mutations detection are still scarce. Bhattacharya D et al. successfully developed an allele-specific quantitative PCR with combination of locked nucleic acid primers and a minor groove binder probe for the quantitative determination of minor viral quasispecies of the triple combination mutation rtV173L+rtL180M+rtM204V within one HBV genome. The assay could accurately detected $3 \times 10^5$ copies of the triple mutant in the $3 \times 10^6$ copies background of wild-type DNA [16].

Though genotypic detection of HBV resistance by AS-PCR using primers containing LNA bases has also been reported by Fang J et al. [17], several improvements were included in our study. There were some differences in primers. Firstly, ambiguity codes were introduced into the primers design because of the polymorphisms in HBV genomes, thereby allowing the primers to hybridize to different genotypes which are common in China. Different polymorphisms in the primer binding region may affect the sensitivity of mutant detection in the presence of the dominant wild type population. To validate detection sensitivity, experiments using non-degenerated primers with exact match to wild type and mutant plasmids were performed. The results indicated that there were no difference in sensitivity between the non-degenerated primers and degenerated primers. Degenerated primers against each pure polymorphic templates (genotype B and C) were also evaluated, whereas the detection sensitivity showed no difference as well. The likely explanations were as follows: On one hand, only two ambiguity codes were included in the forward primer design and only one in the reverse, consequently, the degeneracy is low. On the other hand, the positions of ambiguity codes were in the middle rather than 3'-end of the primers which may have limited influence on sensitivity test. Undoubtedly, the primers meet the degenerated primer design criteria. But the polymorphisms in HBV strains required the use of degenerated primer pairs according to a similar successful primer design described in

| Table 3. Concordance between RT-AS-LNA-qPCR and direct sequencing. |
|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| RT-AS-LNA-qPCR          | Direct sequencing       | Total                   |
|                         | YMDD                    | YMDD+YIDD               | YIDD                    |
| YMDD                    | 85                      | 0                       | 0                       | 85                      |
| YMDD+YIDD               | 3                       | 4                       | 6                       | 13                      |
| YIDD                    | 0                       | 0                       | 4                       | 4                       |
| Total                   | 88                      | 4                       | 10                      | 102                     |

Complete concordant results are shown in bold. Partial concordant results are shown in italics. doi:10.1371/journal.pone.0090029.t003

| Table 4. Partial concordant results between RT-AS-LNA-qPCR and direct sequencing. |
|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| Patient number          | Copy number of HBV DNA(copies/μl) | Mutant/Wild-type ratio | %Mutant/(Mutant+Wild-type) | Sequencing result | Motif |
| Wild-type               | Mutant                  |                          |                          |                        |       |
| 2                       | 9.32E+02                | 8.03E+04                | 86.2                     | 98.9                   | ATT   | YIDD |
| 56                      | 8.24E+05                | 3.47E+06                | 4.2                      | 80.8                   | ATT   | YIDD |
| 11                      | 5.25E+04                | 2.17E+07                | 413.3                    | 99.8                   | ATT   | YIDD |
| 32                      | 2.26E+04                | 1.13E+05                | 5.0                      | 83.3                   | ATT   | YIDD |
| 7                       | 3.31E+05                | 3.21E+06                | 9.7                      | 90.7                   | ATT   | YIDD |
| 86                      | 2.03E+04                | 1.13E+06                | 55.7                     | 98.2                   | ATT   | YIDD |
| 22                      | 3.47E+03                | 3.18E+02                | 0.092                    | 8.4                    | ATG   | YMDD |
| 16                      | 7.02E+04                | 7.63E+03                | 0.11                     | 9.8                    | ATG   | YMDD |
| 65                      | 1.22E+04                | 1.28E+03                | 0.10                     | 9.5                    | ATG   | YMDD |

doi:10.1371/journal.pone.0090029.t004
Ntziora’s research with respect to quantitative detection of the M204V hepatitis B virus minor variants [18]. Secondly, the LNA position of reverse primer specific for the wild-type sequence was at the penultimate position instead of 3’ termini which made it work more specifically. There were different opinions about positions of the nucleic acids locks in the literatures. And there was not a specific guideline on choosing the last position versus the penultimate position for incorporation of the LNA base so far. To a great extent, the position of LNA was determined empirically [16]. Most studies had shown a 3’ LNA residue in the primer at the SNP site (i.e., the mismatch site) could improve mismatch discrimination excellently. Therefore, the LNA nucleotide position in our primers was also chosen at the mismatch site. In a study of effect of locked nucleic acid (LNA) modification position upon representative DNA polymerase and exonuclease activities, Di Giusto et al. reported single LNA at the penultimate (L-2) nucleotide position generated nuclease resistance activity and provided improved discrimination [19]. And a similar successful primer design had also been adopted by Bhattacharya D et al. to quantify minority resistance variants in hepatitis B infection [16]. Inspired by their researches, we introduced an adenine (A) base into Primer L2 to allow LNA to locate at the penultimate to improve the specificity of Primer L2. And we compared the performance of L2 with L2l. It could be seen that the priming efficiency of L2 and L2l were almost the same. When cross-reactivity tests were carried out, the specificity of L2 the was higher than L2l, as evidenced by an increase of the Ct value (ΔΔCt = CtL2 - CtL2l) while 1 × 10^5 ~ 1 × 10^6 copies/μl mutant DNA was added to the PCR reaction system. Consequently, L2 exhibited an advantage over L2l in this study. Beyond that, we also systematically evaluated its performance and clinical application. Besides plasmids, in the present work, clinical materials were used to estimate detection sensitivity and reproducibility of RT-AS-LNA-qPCR. The value of 0.03% was regarded as the sensitivity performed in the clinic. The results from RT-AS-LNA-qPCR and sequencing clearly demonstrated that the two assays showed a high concordance (Kappa = 0.676, P = 0.000). The complete concordance rate between the two assays was 91.2% (93/102). Among 6 partial results (YIDD was detectable by direct sequencing), the quantity of variants were represented 80.8% to 99.8%, a
considerable amount of the total viral population. Among another 3 samples collected from CHB patients who were highly suspicious of drug resistance, only wild-type was detected at rt204 by direct sequencing, but both YMDD and YIDD were detectable by RT-AS-LNA-qPCR. The mutant ratio were 8.4%, 9.0% and 9.5%, respectively, below the sensitivity of direct sequencing. The results from cloning sequencing performed on 3 typical samples whose detected results were partially concordant between direct sequencing and RT-AS-LNA-qPCR were concordant with our established assay. These results indicated that the assay was reliable and sensitive enough to detect minor HBV variants.

Previous studies demonstrated that YMDD variants can be detected about 7 months before clinical breakthrough [7], although different reports differed [20]. In the dynamic observation of virological and biochemical characteristics of a LMV-resistant CHB infection patient, we found that the minor variants can be detected 18 weeks earlier than the rebound of HBV DNA and alanine aminotransferase level. So it may provide useful information for predicting breakthrough hepatitis and adjusting treatment strategies, however, further work focusing on larger-scale sample analysis of its evolution regularity are necessary during follow-up study.

Results obtained from our experimental data showed RT-AS-LNA-qPCR had a much higher analytical sensitivity for detecting minor variants in high wild type background and had several advantages over direct sequencing. Moreover, the assay is SYBR Green 1-based quantitative real-time PCR, and there is no need to design target-specific probes, which is an inexpensive and easily extended method. In addition, instead of \( \Delta \Delta C_t \) calculation method, the assay uses standard curves in each run to absolute quantification wild type and mutant DNA amount, therefore, the accuracy of our assay is much more trustworthy.

Though RT-AS-LNA-qPCR showed excellent characteristics, some limitations were observed as well. Firstly, the specificity of wild-type primer is a little poor, the amplification of the mutant template with the wild-type primer occurred at a mutant viral concentration above \( 1 \times 10^6 \) copies/\( \mu l \), but, the observed copy number was less than the expected copy number at least 4 logs. There were evidences that nonspecific priming phenomena caused by AS-PCR cannot be completely avoided [11–13]. The different degrees of specificity between wild-type and mutant primers may be due to different primer-template mismatch types [21]. However, no nonspecific products occurred when mutant DNA level was below \( 1 \times 10^5 \) copies/\( \mu l \). As the quantity of HBV DNA level is relatively low (below \( 1 \times 10^6 \) copies/\( \mu l \)) in patients with NAs treatment and two separate PCR including wild-type and mutant reaction tubes were run in parallel, the limitation can be ignored to some extent. Secondly, mutant primer was only designed for ATT, however, there are three codons coding for isoleucine (ATT, ATC, and ATA). It should be noted that ATC and ATA were omitted in this study. It remains unclear how quickly the minor variants will become the dominant and what mutant-to-wild-type ratio may cause treatment failure. In the follow-up study, we will combine with RT-ARMS-qPCR assay previously established in our laboratory to dynamic monitoring the evolution of HBV during NAs-experienced, so as to provide direct virological evidence for clinic.

In conclusion, a rapid, cost-effective, sensitive, specific and reliable method was developed for the quantification of the dynamic changes of HBV YMDD variants, which was a practical tool for HBV drug-resistant management. Further studies on methodological comparison including ultra-deep pyrosequencing, etc. will be included in our next study.

Supporting Information

Figure S1 Amplification plot of wild-type degenerated primers against each pure polymorphic templates (genotype B and C) for pMD-18-YMDD. (A) Amplification plot with different colors represented different concentrations of pMD-18-YMDD plasmids of genotype B amplified with wild-type degenerated primers which were illustrated in the figure. (B) Amplification plot with different colors represented different concentrations of pMD-18-YMDD plasmids of genotype C amplified with wild-type degenerated primers which were illustrated in the figure.

Figure S2 Efficiency and specificity test of L2 and L2. (A) Amplification plot with different colors represented different concentrations of pMD-18-YMDD plasmids amplified with L2 and L2. primers, respectively, which were illustrated in the figure (curve 1 and 2: \( 1 \times 10^3 \) copies/\( \mu l \); curve 3 and 4: \( 1 \times 10^4 \) copies/\( \mu l \); curve 5 and 6: \( 1 \times 10^5 \) copies/\( \mu l \); curve 7 and 8: \( 1 \times 10^6 \) copies/\( \mu l \)). (B) Amplification plot with different colors represented different concentrations of pMD-18-YMDD plasmids amplified with L2 and L2. primers, respectively, which were illustrated in the figure (curve 1 and 2: \( 1 \times 10^5 \) copies/\( \mu l \); curve 3 and 4: \( 1 \times 10^7 \) copies/\( \mu l \); curve 5 and 6: \( 1 \times 10^6 \) copies/\( \mu l \); curve 7 and 8: \( 1 \times 10^5 \) copies/\( \mu l \)).

Figure S3 Sensitivity of RT-AS-LNA-qPCR in \( 1 \times 10^7 \) copies/\( \mu l \) wild-type DNA background. (A) Amplification plot with different colors represented different concentrations of mutant DNA balanced mixing with \( 1 \times 10^5 \) copies/\( \mu l \) wild-type DNA which were indicated in the figure. (B) Amplification plot with different colors represented different concentrations of mutant DNA balanced mixing with \( 1 \times 10^6 \) copies/\( \mu l \) wild-type DNA which were indicated in the figure.

Figure S4 Sensitivity detection of mutants in \( 1 \times 10^5 \) copies/\( \mu l \) wild-type DNA background using degenerated primer and non-degenerated primer. (A) Amplification plot with different colors represented different copies of mutant DNA balanced mixing with \( 1 \times 10^5 \) copies/\( \mu l \) wild-type DNA, 100% pure wild-type DNA and no-template control respectively amplified with degenerated primer with exact match to mutant plasmid. (B) Amplification plot with different colors represented different copies of mutant DNA balanced mixing with \( 1 \times 10^5 \) copies/\( \mu l \) wild-type DNA, 100% pure wild-type DNA and no-
template control respectively amplified with non-degenerated primer with exact match to mutant plasmid.

(TIF)

References

1. European Association For The Study Of The Liver (2012) EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57: 167–195.
2. Kim SS, Cho SW, Kim SO, Hong SP, Cheong JY (2013) Multidrug-resistant hepatitis B virus resulting from sequential mono-therapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy. J Med Virol 85: 55–64.
3. Chevaliez S, Rodriguez C, Pasolsky JM (2012) New virologic tools for management of chronic hepatitis B and C. Gastroenterology 142: 1303–1313 e1301.
4. Degertekin B, Hussain M, Tan J, Oberhelman K, Lok AS (2009) Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. J Hepatol 50: 42–48.
5. Liu H, Mao R, Fan L, Xia J, Li Y, et al. (2011) Detection of lamivudine- or adefovir-resistant hepatitis B virus mutations by a liquid array. J Virol Methods 175: 1–6.
6. Hong SP, Kim NK, Hwang SG, Chung HJ, Kim S, et al. (2004) Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 40: 837–844.
7. Kirishima T, Okanoue T, Daimon Y, Itoh Y, Nakamura H, et al. (2002) Detection of hepatitis B virus YMDD mutants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 37: 259–265.
8. Latorra D, Campbell K, Wolter A, Hurley JM (2003) Enhanced allele-specific PCR discrimination in SNP genotyping using 3’ locked nucleic acid (LNA) primers. Hum Mutat 22: 79–85.
9. Pallier C, Castera L, Soulier A, Hezode C, Nordmann P, et al. (2006) Dynamics of hepatitis B virus resistance to lamivudine. J Virol 80: 643–653.
10. Solomone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, et al. (2009) Use of massively parallel ultradepth pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol 83: 1718–1726.
11. Lupò J, Larrat S, Hilleret MN, Genni R, Boyer V, et al. (2009) Assessment of selective real-time PCR for quantitation of lamivudine and adefovir hepatitis B virus-resistant strains and comparison with direct sequencing and line probe assays. J Virol Methods 156: 52–58.
12. Punia P, Cane P, Teo CG, Saunders N (2004) Quantitation of hepatitis B lamivudine-resistant mutants by real-time amplification refractory mutation system PCR. J Hepatol 40: 906–909.
13. Wightman F, Walters T, Ayres A, Bowden S, Bartholomeusz A, et al. (2004) Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of Lamivudine-resistant hepatitis B virus strains. J Clin Microbiol 42: 3809–3812.
14. Morandi L, de Biase D, Visani M, Cesari V, De Maglio G, et al. (2012) Allele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutations. PloS one 7: e36084.
15. Strand H, Ingebretsen OC, Nielsen Ø (2008) Real-time detection and quantification of mitochondrial mutations with oligonucleotide primers containing locked nucleic acid. Clin Chim Acta 390: 126–133.
16. Bhattacharya D, Lewis MJ, Lasmann B, Phan T, Knecht G, et al. (2013) Combination of allele-specific detection techniques to quantify minority resistance variants in hepatitis B infection: a novel approach. J Virol Methods 190: 34–40.
17. Fang J, Wicherowski MJ, Levine SM, Baldick CJ, Mazzucco CE, et al. (2009) Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates. Antimicrob Agents Chemother 53: 2762–2772.
18. Ntziora F, Paraskevis D, Haida C, Magiorkinis E, Manesis E, et al. (2009) Quantitative detection of the M204V hepatitis B virus minor variants by amplification refractory mutation system real-time PCR combined with molecular beacon technology. J Clin Microbiol 47: 2544–2550.
19. Di Giusto DA, King GC (2004) Strong positional preference in the interaction of LNA oligonucleotides with DNA polymerase and proofreading exonuclease activities: implications for genotyping assays. Nucleic Acids Res 32: c32.
20. Umroka F, Iwasaki Y, Matsunuma M, Takaki A, Kobashi H, et al. (2006) Early detection and quantification of lamivudine-resistant hepatitis B virus mutants by fluorescent biprobe hybridization assay in lamivudine-treated patients. J Gastroenterol 41: 693–701.
21. Kwok S, Kellogg DE, McKinney N, Spasic D, Goda L, et al. (1990) Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies. Nucleic Acids Res 18: 999–1005.
22. Sun Y, Shen Z, Wu Y, Gao RT, Li Y, Yang Z (2007) Real-time PCR method for monitoring YMDD Motif mutations associated with Lamivudine resistance in patients with HBV infection. Chinese journal of laboratory medicine 30: 533–537.

Author Contributions

Conceived and designed the experiments: YZ QO BY. Performed the experiments: YZ DL WW JL. Analyzed the data: YZ DL MS JC. Contributed reagents/materials/analysis tools: LJ BY QO JL. Wrote the paper: YZ HC JL.